Background: This analysis was conducted to evaluate the efficacy and safety of a combination of gemcitabineand nedaplatin in treating patients with non-small cell lung cancer.
Methods: Clinical studies evaluating theefficacy and safety of a combination of gemcitabine and nedaplatin with attention to response and safety forpatients with non-small cell lung cancer were identified using a predefined search strategy. Pooled responserates for gemcitabine and nedaplatin were calculated.
Results: In gemcitabine and nedaplatin based regimens, 4clinical studies including 112 patients with non-small cell lung cancer were considered eligible for inclusion. Thepooled analysis suggested that the pooled reponse rate was 40.2% (45/112). Main side effects included grade 3-4neutropenia, thrombocytopenia, and anemia. Grade 3-4 nonhematological toxicity included nausea and vomiting,diarrhea, and hepatic dysfunction. There were no treatment-related deaths.
Conclusion: This evidence basedanalysis suggests that the combination of gemcitabine and nedaplatin is associated with good response rate andaccepted toxicity for treating patients with non-small cell lung cancer.